AbbVie Inc.

AbbVie Inc.

ABBVNYSE / NASDAQHealthcareLarge cap

$286.20+$2.66 (+0.9%)

Last close · Data as of Nov 20, 2026

Market cap
$397.4B
P/E
94.9x
EV / EBITDA
26.1x
Revenue
$61.2B
Net margin
6.8%
ROCE
14.8%

+24.7% over the last year

AbbVie Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-1.0%
3M
+9.3%
6M
+34.8%
1Y
+24.7%
5Y
+146.2%

52-week range

Day change +$2.66 (+0.9%) from $284 to $286 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in ABBV, bought on each weekday since 2021.

News & filings

What AbbVie filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernShareholders' equity is negative: liabilities exceed assets.

Strengths (1)

  • Operating margin of 32.8% against a peer median of 25.9%.
  • Shareholders' equity is negative, so return on equity and debt to equity are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.

Read moreShow less

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Sector
Healthcare
Shares outstanding
1.77B

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$397.4B
P/E
94.9x
EV / EBITDA
26.1x
EV / Sales
7.5x
P/S
6.5x
52-week high
$295.03
52-week low
$197.38

Profitability

Operating margin
32.8%
Net margin
6.8%
EBITDA margin
28.8%
ROE
-128.0%
ROCE
14.8%
ROA
3.1%
Asset turnover
0.46

Growth

Revenue
$61.2B
Revenue growth, 1Y
8.6%
Revenue CAGR, 3Y
1.8%
Net profit growth, 1Y
-1.2%
Free cash flow
$17.8B

Solvency

Current ratio
0.67
Debt / Assets
0.50
CFO / Net profit
4.55
Cash / Market cap
1.3%

Where the revenue went

Of every $100 of FY2025 revenue, $7 was left as net income.

AbbVie Inc. income statement flow, FY2025
AbbVie Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$18.2B
RevenueGross profit$43.0B
Gross profitOperating expenses$22.9B
Gross profitOperating income$20.1B
Operating incomePretax income$6.6B
Operating incomeInterest and other expense$13.5B
Pretax incomeTax and other$2.4B
Pretax incomeNet income$4.2B

Revenue and net profit

Revenue grew 8.6% in FY2025; net profit is the dashed line.

AbbVie Inc. revenue and net profit by fiscal year
AbbVie Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$58.1B$11.8B
FY2023$54.3B$4.9B
FY2024$56.3B$4.3B
FY2025$61.2B$4.2B

Cash flows

FY2025: $19.0B from operations, $17.8B free after investment (dashed).

AbbVie Inc. operating and free cash flow by fiscal year
AbbVie Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$24.9B$24.2B
FY2023$22.8B$22.1B
FY2024$18.8B$17.8B
FY2025$19.0B$17.8B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$61.2B+8.6%1Y
EBITDA
$17.6B+18.2%1Y
Net profit
$4.2B-1.2%1Y
Cash from operations
$19.0B+1.2%1Y
Free cash flow
$17.8B-0.1%1Y
Revenue CAGR, 3Y
1.8%
Net profit CAGR, 3Y
-29.1%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$61.2B$17.6B$4.2B$17.8B-129.2%+8.6%-1.2%

Monthly returns

Month-by-month returns of ABBV across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$134.0B
Liabilities$137.2B
Equity-$3.2B
Paid-in capital$22.5B
Retained earnings-$15.5B
Treasury stock$9.1B
Minority interest$42.0M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; ABBV highlighted.

P/E against peers

ABBV trades at 94.9x earnings against a peer median of 24.2x (a 292% premium).

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
AbbVie Inc.ABBVthis companyP/E ↑ premium$397.4B94.9x—-128.0%26.1x
Johnson & JohnsonJNJ$549.3B20.5x6.7x32.9%14.1x
UnitedHealth Group IncorporatedUNH$360.1B29.9x3.8x12.8%18.0x
Merck & Co., Inc.MRK$297.0B16.3x5.6x34.7%11.7x
Amgen Inc.AMGN$186.5B24.2x21.5x89.1%13.7x
Thermo Fisher Scientific Inc.TMO$179.1B26.7x3.4x12.6%18.1x
Gilead Sciences, Inc.GILD$160.4B18.8x7.1x37.5%12.9x
Abbott LaboratoriesABT$158.1B24.2x3.0x12.5%13.5x
Intuitive Surgical, Inc.ISRG$148.3B51.9x8.3x16.0%39.3x
Peer median—24.2x6.2x24.4%13.9x

Year-to-date ROI

ABBV since 1 January, against earlier years.

Historical volatility

ABBV's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

AbbVie Inc. operating margin by fiscal year
AbbVie Inc. operating margin by fiscal year
DateOperating margin
FY202232.4%
FY202324.9%
FY202421.1%
FY202532.8%
LineFY2025
Cost of revenueCost Of Revenue$18.2B
Gross profitGross Profit$43.0B
Operating expensesOperating Expense$22.9B
Research and developmentResearch And Development$9.1B
Selling, general and administrativeSelling General And Administration$14.0B
Other operating expensesOther Operating Expenses-$241.0M
Total expensesTotal Expenses$41.1B
Pretax incomePretax Income$6.6B

Learn while you research

Academy chapters picked for AbbVie Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 94.9, learn when high multiples are justified.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →